Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
28 verified discoveries match your filters.
In the randomized, phase 3 ECOG-ACRIN E1910 trial, adding blinatumomab to consolidation chemotherapy significantly extended overall survival compared with chemotherapy alone in adults with MRD-negative B-cell precursor ALL — the…
Primary source cited
Last reviewed
In the LIBRETTO-121 trial's primary efficacy population of 25 pediatric and young adult patients with RET-altered solid tumors (including RET-altered thyroid cancer) that had not responded to available therapies, selpercatinib…
Primary source cited
Last reviewed
In two separate, randomized, double-blind, phase 3 trials (SPOTLIGHT and GLOW), adding zolbetuximab to first-line chemotherapy significantly extended both progression-free survival and overall survival, compared with chemotherapy alone, in patients…
Primary source cited
Last reviewed
A population-based analysis of national mortality data in England (2001-2024) found a substantial reduction in cervical cancer mortality among women aged 20-29 associated with high uptake of England's HPV vaccination…
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 innovaTV 301 trial, tisotumab vedotin significantly extended both overall survival (11.5 months versus 9.5 months) and progression-free survival (4.2 months versus 2.9 months), compared…
Primary source cited
Last reviewed
In the single-arm, phase 2 FIREFLY-1 trial, tovorafenib produced an objective response (tumor shrinkage or resolution) in about 67% of children and young adults with relapsed or refractory, BRAF-altered pediatric…
Primary source cited
Last reviewed
The FDA granted 510(k) clearance -- a real FDA regulatory action for a diagnostic device, distinct from the drug-approval pathway most other records on this site describe -- to Ibex…
Primary source cited
Last reviewed
In the single-arm, open-label, phase 1/2 MonumenTAL-1 trial, talquetamab produced meaningful, durable responses in patients with heavily pretreated, relapsed or refractory multiple myeloma who had already exhausted the major available…
Primary source cited
Last reviewed
In the randomized, phase 3 CodeBreaK 300 trial, sotorasib plus panitumumab significantly extended progression-free survival (5.6 months vs 2.0 months, hazard ratio 0.48) and improved objective response rate (26% vs…
Primary source cited
Last reviewed
In the prospective, 20,176-participant BLUE-C study, Cologuard Plus (a next-generation multitarget stool DNA test) detected colorectal cancer with 95% sensitivity and correctly identified 94% of participants without colorectal cancer or…
Primary source cited
Last reviewed